Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system)

Assess current results for time in therapeutic range for people currently on vitamin K antagonist therapy to make a case for change. See measuring success for further details.

Identify the potential demand for self-monitoring among people with atrial fibrillation or heart valve disease who are taking vitamin K antagonists. See insights from the NHS for further details.

Identify how the service will be measured in terms of quality and safety, patient experience, productivity and improved clinical outcomes. See measuring success for further details.

Develop clear selection and training criteria for the service. See education for an example.

Develop local protocols for supporting people to self-monitor. See development of local documentation for examples.

Ensure that all supporting staff have training on the use and quality assurance of coagulometers. See insights from the NHS for further details.

Commissioners and providers need to work together to assess the whole system cost benefit to the widespread adoption of self-monitoring. See business case development for further information.